Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 5Neoplasm Metastasis 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Sarcoma 1Recurrence 1Neoplasm, Residual 1Melanoma 1Lung Neoplasms 1Core Binding Factor Acute Myeloid Leukemia 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 21Cytarabine 15blinatumomab 13fludarabine 12Azacitidine 10venetoclax 9fludarabine phosphate 9Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Rituximab 6Mercaptopurine 6Daunorubicin 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Etoposide 4Busulfan 4obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm, Residual × avapritinib × Clear all
NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Recruiting
120 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡